Handok, Genexine to join forces in co-development of new drugs

Published: 2012-02-07 06:57:00

Updated: 2012-02-07 06:57:00

Handok Pharmaceutical and Genexine Co., a drug development biotech, agreed to join hands to develop biobetters and biodrugs so that they can stay competitive with its foreign rivals.

The two companies signed a memorandum of understanding on Thursday to develop and commercialize the sustained-release treatments for autoimmune diseases and hemophilia using Genexine's proprietary hybrid Fc-fusi...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.